Company intelligence / Profile preview

NovaCardia

San Diego, California, United Statesreuters.com ↗

Ownership: Private
Development stage: Phase 3

Overview

NovaCardia was a clinical-stage pharmaceutical company focused on developing and commercializing compounds for cardiovascular diseases. Its lead compound, rolofylline (KW-3902), an adenosine A1 receptor antagonist for acute heart failure, reached Phase 3 clinical trials before the company's acquisition by Merck & Co. in 2007. Preliminary results from a pilot Phase 3 trial were presented at the European Society of Cardiology prior to acquisition

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

KW-3902

Phase 3

Indications: Acute congestive heart failure

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on NovaCardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaCardia.

Explore the full profile